Ramipril With FelodipineTriasyn
Treatment of hypertension in patients not adequately controlled with either ramipril or felodipine monotherapy, or receiving both concomitantly.
Access path
- TGA registered · Triasyn
TGA label narrower than the PBS population
- Mar 2007Recommended · restricted
Comparator changed: ramipril and felodipine extended release (ER) monotherapies →…
- Mar 2007Recommended · restricted
Comparator changed: ramipril and felodipine extended release (ER) monotherapies →…
- PBS listing · Restricted
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated by design.
The PBAC recommended listing on a cost-minimisation basis compared with the corresponding strengths of the ramipril and felodipine components given concomitantly. PBAC · 2007
Decision context
PopulationPatients with mild to moderate hypertension not adequately controlled with either ramipril or felodipine monotherapy, or receiving both concomitantly.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2007 | Recommended · restricted | ramipril and felodipine extended release (ER) monotherapies | — | RCT |
| Mar 2007 | Recommended · restricted | ramipril and felodipine extended release monotherapies | — | RCT |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients inadequately controlled with prior ramipril or felodipine monotherapy; TGA label covers all mild-to-moderate hypertension.